Mayo clinic tests best duration of maintenance therapy for rare blood disease

NCT ID NCT05898646

First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study looks at whether a shorter or longer course of daratumumab maintenance therapy works better for people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 96 adults who have already responded to initial daratumumab treatment will be assigned to either 1 or 3 years of maintenance. The goal is to see which approach helps keep the disease from coming back and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.